New York Launches First State-Led Cannabis IBD Study

New York Becomes First State to Fund Cannabis IBD Clinical Research

New York's Office of Cannabis Management (OCM) has launched what it calls the first state-led clinical research study examining how cannabinoids affect patients with inflammatory bowel disease. The pilot study, formally titled "A Pilot Prospective Observational Study to Assess the Effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on Inflammatory Bowel Disease Symptoms," represents a new chapter in state-level cannabis research, one made possible by the federal rescheduling of medical cannabis to Schedule III.

The study arrives at a moment when millions of Americans living with Crohn's disease and ulcerative colitis are already turning to cannabis on their own. A study published earlier this year found that 87.5 percent of IBD patients using CBD reported symptom relief. But the evidence base remains thin, and physicians have had little rigorous data to guide their recommendations. New York's initiative aims to change that.

How the Study Works

The research design is observational, meaning participants will not be randomly assigned to treatment groups. Instead, adults aged 18 and older with a diagnosed moderate form of IBD will receive oral doses of CBD and THC and be monitored for changes in quality of life, symptom severity, and overall well-being.

Several licensed cannabis providers are partnering with the state to supply regulated products for the study. Vireo Health, Rise Dispensaries, and Citiva Medical are among the dispensary partners facilitating participant enrollment and product access. This public-private model ensures that study participants receive standardized, lab-tested products rather than the variable formulations available on the consumer market.

One notable requirement stands out: participants must commit to abstaining from smoking marijuana for the duration of the study. This restriction allows researchers to isolate the effects of oral cannabinoid administration without the confounding variable of inhaled cannabis, which has different pharmacokinetics and bioavailability profiles.

Why IBD Is the Focus

Inflammatory bowel disease affects an estimated 3.1 million adults in the United States, according to the Centers for Disease Control and Prevention. The two primary forms, Crohn's disease and ulcerative colitis, involve chronic inflammation of the gastrointestinal tract that can cause debilitating pain, urgent and frequent bowel movements, fatigue, and malnutrition.

Current standard-of-care treatments include immunosuppressants, biologics, and corticosteroids, all of which carry significant side effect profiles and don't work for every patient. Approximately 30 to 40 percent of IBD patients do not respond adequately to existing therapies, creating a substantial unmet medical need.

The endocannabinoid system, which includes CB1 and CB2 receptors distributed throughout the gastrointestinal tract, has long been a theoretical target for IBD treatment. Preclinical research has shown that cannabinoids can modulate intestinal inflammation, reduce gut motility, and decrease visceral pain signaling. But translating those laboratory findings into clinical practice has been slow, partly because of the regulatory barriers that existed under cannabis's former Schedule I classification.

The Schedule III Difference

Federal rescheduling has been a game-changer for cannabis research. Under Schedule I, researchers faced months-long approval processes, severe restrictions on the types and quantities of cannabis they could use, and limited access to research-grade material. Schedule III retains federal oversight but dramatically simplifies the approval pathway.

New York's OCM has been positioning itself to capitalize on this shift. Governor Hochul's administration invested $17 million in social and economic equity initiatives for the cannabis industry in 2026, and the IBD study represents the research arm of that broader commitment to building an evidence-based cannabis market.

The timing also matters for the research community. Over 100 notable cannabis studies have been published so far in 2026, covering everything from pain management and cancer treatment to neurodegenerative diseases and metabolic disorders. New York's IBD study adds to a growing body of state-sponsored research that is filling gaps the federal government has been slow to address.

What Previous Research Shows

The scientific literature on cannabis and IBD is promising but incomplete. A 2026 study published in JGH Open surveyed gastroenterology outpatients and found that 87.5 percent of those using CBD reported improvement in at least one IBD symptom. The most commonly cited benefits were reduced abdominal pain, improved sleep, and decreased anxiety related to their condition.

However, the same study highlighted important caveats. Self-reported symptom improvement does not necessarily correlate with objective measures of inflammation, such as endoscopic findings or biomarker levels. Patients may feel better subjectively while their underlying disease activity remains unchanged or even worsens.

A separate population-based longitudinal study published in Inflammatory Bowel Diseases examined cannabis use among IBD patients and found mixed results. While some patients reported symptomatic improvement, the study identified potential risks including increased healthcare utilization among heavy cannabis users and possible interactions with conventional IBD medications.

These conflicting findings underscore why controlled, prospective studies like New York's are essential. Anecdotal evidence and retrospective surveys can generate hypotheses, but only well-designed clinical research can establish causation and guide treatment protocols.

Implications for Patients and Providers

For the estimated 200,000 New Yorkers living with IBD, the study offers a potential pathway to more informed treatment decisions. Participants who enroll will receive medical-grade cannabis products at no cost through the partnering dispensaries and will be monitored by healthcare providers familiar with both IBD management and cannabis therapeutics.

For physicians, the study addresses a persistent clinical dilemma. Many gastroenterologists report that their patients ask about cannabis, but few feel equipped to provide evidence-based guidance. A state-sponsored study with published results could give providers the data they need to have more productive conversations with their patients.

The OCM has indicated that findings from the study will be made publicly available and may inform future medical cannabis policy in New York. If the results are positive, they could lead to IBD being added to the state's qualifying conditions for medical cannabis certification, streamlining access for patients who might benefit.

The Bigger Picture for Cannabis Research

New York's IBD study is part of a broader national trend toward state-level cannabis research initiatives. Universities across the country have ramped up their cannabis research programs since rescheduling, with the University of California system alone running multiple clinical trials examining cannabinoids for conditions ranging from chronic pain to epilepsy.

The OCM study is distinctive because it is the first to be designed, funded, and administered by a state cannabis regulatory agency rather than a university or private research institution. This model could be replicated by other states looking to build their own evidence bases for cannabis policy decisions.

For the cannabis industry, these research investments serve a dual purpose. They provide the clinical data needed to support medical claims and product development, and they help legitimize the industry in the eyes of healthcare providers, insurers, and policymakers who have been skeptical of cannabis's therapeutic potential.

How to Participate

New Yorkers interested in enrolling in the study can find information through the OCM's website and the participating dispensary partners. Eligibility requires a documented IBD diagnosis, age 18 or older, and willingness to use only oral cannabis products during the study period.

The study represents a meaningful step forward in understanding how cannabinoids interact with inflammatory bowel disease. Whether it confirms the therapeutic promise that patients have long reported or reveals limitations that temper expectations, the data it generates will be valuable. In a field that has been long on anecdote and short on evidence, New York is betting that rigorous research is the path forward.

For readers building a list of operators, the Budpedia cannabis dispensary directory tracks verified storefronts across every legal state — useful for cross-referencing the businesses and policy shifts covered above.